Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development




Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

BEIJING–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies.

Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice^® fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies.

Dr. Yuelei Shen, President and CEO of Biocytogen, said, “BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice^® fully human antibody platform, highlighting our ability to empower partners in driving innovative drug discovery. We look forward to seeing these promising molecules progress rapidly into the clinic and ultimately bring transformative treatment options to patients worldwide.”

Under the terms of the agreement, Biocytogen will receive an upfront payment from BeOne Medicines. In addition, Biocytogen is eligible to receive development and regulatory milestone payments, commercial milestone payments, and tiered royalties based on future net sales of licensed products.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice^® (RenMab^™/ RenLite^®/ RenNano^®/ RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice^® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.

Contacts

Biocytogen Contacts
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

AHF: Gilead’s Greed Costs Latin America HIV Protection




AHF: Gilead’s Greed Costs Latin America HIV Protection

MEXICO CITY–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir. Today’s announcement of a pricing and procurement deal between Gilead and the Global Fund to Fight AIDS, Tuberculosis and Malaria leaves most countries in the region out, forcing them to negotiate individually and in secrecy.

“Once again, Latin America and the Caribbean have been pushed to the margins of progress,” said Dr. Patricia Campos, AHF Bureau Chief for Latin America and the Caribbean. “While we applaud efforts to expand access elsewhere, our region is left to fend for itself—facing rising HIV rates, shrinking foreign aid, and now the added burden of opaque pricing negotiations with a pharmaceutical giant that prioritizes patents over people.”

The Global Fund’s deal with Gilead represents a potential step forward for some low- and middle-income countries. AHF acknowledges and deeply values the Global Fund’s life-saving work, especially during this period of economic uncertainty and reductions in foreign aid. However, the terms of this new agreement underscore the persistent inequalities in access to medical innovation—inequalities driven not by science but by corporate profit motives.

According to Gilead’s own announcement, many Latin American countries with high HIV burdens “are not covered by this agreement.” These countries were also excluded from the company’s earlier licensing arrangement for generic production of lenacapavir, leaving them at the mercy of Greedy Gilead’s closed-door pricing policies and monopolistic control.

AHF strongly opposes secret pricing agreements and reiterates its call for transparency, equity, and public accountability in global access to HIV prevention.

In solidarity with Public Citizen and more than 100 civil society organizations across the region, AHF urges governments in Latin America and the Caribbean to:

• Strengthen legal frameworks to enable compulsory licensing of essential medicines;
• Challenge evergreening patents through patent oppositions;
• Declare long-acting PrEP drugs like lenacapavir as medicines of public interest, unlocking pathways for affordable generic competition.

Countries like Colombia, which recently issued a compulsory license for the HIV medication dolutegravir, are setting an important precedent. Other governments in the region must urgently follow suit to overcome pharmaceutical barriers and scale up prevention.

“The science is ready. The tools are available. What’s missing is equitable access—and that is something governments can and must act on now,” said Guillermina Alaniz, AHF Director of Global Advocacy & Policy, based in Argentina. “Together with Public Citizen and a growing coalition of civil society allies, we are building momentum across Latin America to challenge unjust monopolies and ensure lifesaving HIV prevention reaches everyone—no matter where they live.”

AIDS Healthcare Foundation (AHF) is a global non-profit organization providing cutting-edge medicine and advocacy to over 2.3 million people in 48 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. We are currently the largest non-profit provider of HIV/AIDS medical care in the world. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare

Contacts

MEDIA CONTACTS:

Sergio Lagarde Moguel
Marketing, Advocacy & PR Director

AHF Latin America & Caribbean Bureau

ahflatamcaribe@aidshealth.org
+52 5519315156

Denys Nazarov
Director of Global Policy and Communications

AIDS Healthcare Foundation (US)

denys.nazarov@aidshealth.org
+1 323.308.1829

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer




Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free Latitude™ MRD assay, which were presented at the 2025 European Society for Medical Oncology GI Congress (ESMO GI).

The clinical performance of the assay was analyzed in a cohort of ~200 patients (>1,300 plasma samples) with resectable stage I-IV colorectal cancer. Samples were derived from the GALAXY arm of the CIRCULATE-Japan study, one of the largest and most comprehensive prospective studies of MRD testing in resectable CRC. Key results include:

• Excellent clinical sensitivity to recurrence: The Latitude assay detected recurrence with 58% sensitivity in the post-surgical MRD window and 81% sensitivity in the surveillance setting, with median diagnostic lead time of 4.6 months.

• High clinical specificity: In the surveillance setting, patient-level specificity was 92%, and sample-level specificity was 97%.

• Highly prognostic of recurrence risk: MRD positivity was significantly associated with inferior outcomes during both the MRD (HR: 10, p<0.001) and surveillance (HR: 18, p<0.001) windows.

• Highly predictive of adjuvant chemotherapy (ACT) benefit: Among high-risk stage II and stage III patients, those who were MRD-positive after surgery derived significant benefit from ACT (p<0.001), while no significant treatment benefit was observed in MRD-negative patients (p=0.54).

“This study demonstrates strong clinical potential for Natera’s tissue-free MRD assay,” said Yoshiaki Nakamura, M.D., Ph.D., principal investigator of the study. “We clearly observed the prognostic and predictive value of the assay, seeing strong correlation of recurrence risk and adjuvant treatment outcomes.”

“These results reinforce the data previously presented at ASCO GI, where our tissue-free Latitude MRD assay demonstrated high overall concordance to Signatera™ as well as strong standalone clinical performance,” said Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera. “When offered alongside Signatera, our tissue-free assay gives patients and providers the latitude to get a reliable MRD assessment even when tissue is unavailable.”

Notes

^*MRD = Molecular residual disease

About Natera

Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in “Risk Factors” in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

Contacts

Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema




KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

First new on-demand HAE treatment in over a decade, with potential to transform management of the disease

Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, and well-established safety profile

Management to host conference call today at 8:30 a.m. ET

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY^® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE.

“The FDA approval of EKTERLY is a defining moment for people living with HAE,” said Ben Palleiko, CEO of KalVista. “EKTERLY enables people to treat attacks the moment symptoms begin, wherever they are. This approval affirms the strength of our science and deep commitment to the HAE community. I am profoundly grateful to the KalVista team for their dedication and perseverance, and to the patients and healthcare providers, as well as the HAEA and HAEi, for making this possible. EKTERLY has the potential to become the foundational treatment for HAE and our focus now is on delivering it to the people who need it.”

“As the first orally administered on-demand therapy for HAE attacks, EKTERLY provides patients and physicians with an important and welcome advance in HAE treatment options,” said Anthony J. Castaldo, chief executive officer of the U.S. Hereditary Angioedema Association.

Prior to EKTERLY’s approval, all on-demand HAE treatment options approved in the U.S. required intravenous or subcutaneous administration, which carries a significant treatment burden.¹ Even with the use of long-term prophylaxis as a preventative therapy, most people living with HAE continue to have unpredictable attacks and require ready access to on-demand medication.¹

“This is an important moment for patients, giving people living with HAE a treatment option that could provide greater independence and control over managing their condition,” said Marc A. Riedl, MD, Professor of Medicine and Clinical Director, U.S. Hereditary Angioedema Association Center at the University of California, San Diego, and an investigator for the KONFIDENT phase 3 trial. “Until now, on-demand treatment relied on injectable subcutaneous or intravenous administration, often resulting in delayed intervention. Having an oral option empowers patients to treat attacks early, which aligns with treatment guidelines and advances our goal as physicians to reduce the overall burden of disease.”

The efficacy and safety of EKTERLY was established by the results from KalVista’s phase 3 KONFIDENT clinical trial, which was the largest clinical trial program ever conducted in HAE. Data from KONFIDENT was published in the New England Journal of Medicine in May 2024, showing that EKTERLY achieved significantly faster symptom relief, reduction in attack severity and attack resolution than placebo, and was well-tolerated with a safety profile similar to placebo.² The trial randomized 136 HAE patients from 66 clinical sites across 20 countries. These results were further supported by the more real-world KONFIDENT-S open-label extension trial, which as of September 2024, showed that EKTERLY enabled patients to treat attacks in a median of 10 minutes following onset. The most recent data from KONFIDENT-S shows that beginning of symptom relief occurred in a median of 1.3 hours among attacks involving the larynx, the abdomen, and for breakthrough attacks among patients receiving long-term prophylaxis. The safety profile of EKTERLY 600 mg in KONFIDENT-S, in a much larger number of attacks (>1700), was consistent with that observed in KONFIDENT.

KalVista will launch EKTERLY in the U.S. immediately and physicians can begin writing prescriptions today. As part of the Company’s commitment to supporting patients, KalVista has established KalVista Cares™, a comprehensive patient support program that offers personalized services and resources for eligible individuals. This includes assistance with navigating insurance coverage, access support, and ongoing help throughout the treatment journey.

For more information, visit EKTERLY.com.

Conference Call and Webcast

KalVista will host a live conference call and webcast to discuss the FDA approval of EKTERLY today, July 7, 2025, at 8:30 a.m. ET. The webcast will be accessible through the Investors section of the Company’s website at ir.kalvista.com. A replay will be available shortly after the conclusion of the live event.

About Hereditary Angioedema

Hereditary angioedema (HAE) is a rare genetic disease resulting in deficiency or dysfunction in the C1 esterase inhibitor (C1INH) protein and subsequent uncontrolled activation of the kallikrein-kinin system. People living with HAE experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected. Treatment guidelines recommend treating attacks as early as possible to prevent progression of swelling and shorten the time to attack resolution, and to consider treatment for all attacks, regardless of anatomic location or severity.

About EKTERLY^® (sebetralstat)

EKTERLY (sebetralstat), a novel plasma kallikrein inhibitor, is the first and only oral on-demand therapy approved by the U.S. FDA for the treatment of acute attacks of hereditary angioedema (HAE) in people 12 years of age and older. With ongoing studies exploring its use in children aged two to 11 and multiple regulatory applications under review in key global markets, EKTERLY has the potential to become the foundational therapy for HAE management worldwide.

INDICATION AND IMPORTANT SAFETY INFORMATION

What is EKTERLY^® (sebetralstat)?

EKTERLY is a prescription medicine used to treat sudden (acute) attacks of hereditary angioedema (HAE) in adults and children aged 12 years of age and older. It is not known if EKTERLY is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

Before taking EKTERLY, tell your healthcare provider about all of your medical conditions, including if you:

• Are pregnant or planning to become pregnant. It is not known if EKTERLY can harm your unborn baby.
• Are breastfeeding or plan to breastfeed. It is not known if EKTERLY passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while taking EKTERLY.
• Have liver problems.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking EKTERLY with certain other medicines can cause side effects or affect how well EKTERLY or the other medicines work. Especially tell your healthcare provider if you take any of the following, as their use with EKTERLY is not recommended: itraconazole, phenytoin, efavirenz.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

What are the possible side effects of EKTERLY?

The most common side effects of EKTERLY include headache. For more information, ask your healthcare provider or pharmacist. Talk to your doctor for medical advice about side effects.

You are encouraged to report side effects related to KalVista products by calling 1-855-258-4782. If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click here for full Prescribing Information, including Patient Information.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. In the U.S., KalVista markets EKTERLY^®, the first and only oral on-demand treatment for hereditary angioedema (HAE). The Company has multiple regulatory applications under review in key global markets. For more information about KalVista, please visit www.kalvista.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, information relating to our business and business plans, the success of our efforts to commercialize EKTERLY^® (sebetralstat), our ability to successfully obtain foreign regulatory approvals for sebetralstat, our expectations about the safety and efficacy of sebetralstat and our other product candidates, the timing of clinical trials and their results, our ability to commence clinical studies or complete ongoing clinical studies, including our KONFIDENT-S and KONFIDENT-KID trials, and the ability of EKTERLY to treat HAE. Further information on potential risk factors that could affect our business and financial results are detailed in our filings with the Securities and Exchange Commission, including in our annual report on Form 10-K for the year ended April 30, 2024, our quarterly reports on Form 10-Q, and our other reports that we may make from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts

Ryan Baker

Head, Investor Relations

(617) 771-5001

ryan.baker@kalvista.com

Molly Cameron

Director, Corporate Communications

(978) 339-3378

molly.cameron@kalvista.com

Federal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVAC




Federal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVAC

Court denies Vivo Capital’s petition for relief relating to shareholder votes and corporate governance, clearing another legal hurdle for distribution of the US$55.00 per common share special cash dividend

Marks fourth unsuccessful legal attempt in deceptive and disparaging campaign by Advantech/Prime or Vivo Capital against current Board and its Chairman

New reports from two leading independent proxy advisory firms, Glass Lewis and ISS, firmly recommend shareholders vote to KEEP the current Board chaired by Dr. Chiang Li

BEIJING–(BUSINESS WIRE)–The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that on June 30, the United States District Court for the District of Massachusetts denied Vivo Capital’s petition against 1Globe Capital LLC (“1Globe”) for relief relating to SINOVAC’s shareholder votes and corporate governance. In its ruling, the Court concluded, “relief relating to governance outcomes or shareholder votes – are DENIED without prejudice.”

The Massachusetts ruling marks the fourth unsuccessful legal attempt by either Advantech/Prime Success (“Advantech/Prime”) or Vivo Capital (together “the Dissenting Investor Group”) to strip SINOVAC common shareholders of their rightful dividend payments. This result follows Advantech/Prime’s recently failed petition in New York and Advantech/Prime and Vivo Capital’s recently failed petition in Hong Kong – which were repeated attempts to block or delay a hearing for interim relief sought by the Company et al at the Antiguan High Court and to interfere with the Company’s payment of the US$55.00 per common share special cash dividend declared by the current SINOVAC Board. The Dissenting Investor Group continues to interfere with the current Board’s fiduciary duties to implement the UK Privy Council’s unappealable ruling in January 2025. In this ruling, the UK Privy Council deemed the former illegitimate board an “Imposter Board” and handed 1Globe – the investment arm of a cancer-focused global R&D group and SINOVAC’s largest shareholder – a victory on all grounds. In addition, the UK Privy Council Judicial Committee, comprising five UK Supreme Court Justices, concluded that there was “nothing unlawful in the conduct of 1Globe” in connection with SINOVAC’s 2018 AGM.

The Dissenting Investor Group’s self-serving, multi-pronged lawfare strategy is crystal clear: (1) block actions taken by the SINOVAC Board to distribute rightful dividend payments to valid SINOVAC common shareholders; (2) protect the ill-gotten gains it stripped from SINOVAC subsidiaries over the past seven years; and (3) regain control of SINOVAC in order to continue to loot the Company. Having failed in the courtroom, the Dissenting Investor Group has decided to instead use deceptive and false stories to attack 1Globe and its founder Dr. Chiang Li, who chairs the current SINOVAC Board. As noted in SINOVAC’s proxy materials, Dr. Li is an accomplished clinician, scientist, inventor, entrepreneur and a seasoned executive with international recognitions. Dr. Li and 1Globe have successfully challenged the Dissenting Investor Group’s abuse in court for the past seven years and championed the rights and interests of all valid SINOVAC shareholders.

During those seven years, The Dissenting Investor Group, in coordination with the former illegitimate board (the “Imposter Former Board”), pursued the following schemes:

1. Privatization attempt at a below-market price in 2016, which would have succeeded had it not been for the efforts of 1Globe (who declined an invite by the Former Management Buyout Group to join and profit from its privatization attempt);
2. Invalid PIPE transaction at a below-market price in 2018, which materially diluted SINOVAC shareholders and was made at a time when the Company did not need the capital;
3. Commitment by the Imposter Former Board to invest ~US$139 million of SINOVAC cash into a venture fund managed by Vivo Capital – creating a clear conflict of interest. This would be in addition to the approximately US$100 million SINOVAC has already invested into Vivo Capital funds.
4. US$15 million debt investment into Sinovac Life Sciences Co., Ltd. (“SLS”), a wholly owned subsidiary of SINOVAC, in exchange for a 15% equity interest in SLS in 2020, at a time when the Company did not need the capital and which has resulted in over US$1 billion of distributions made to the Dissenting Investor Group. In contrast, SINOVAC common shareholders have received no dividends and haven’t been able to trade their shares for the past six years. To add insult to injury, the Imposter Former Board publicly stated in April 2024 in the Company’s 2023 20-F that it had “no plan to pay any cash dividends on SINOVAC Antigua’s shares in the foreseeable future”;
5. Barrage of baseless and wasteful legal action in 2025, after refusing to accept the Privy Council’s non-appealable ruling, with the goal of interfering with the dividend payment unless the Dissenting Investor Group is able to double dip on dividends already received from SLS;
6. Deceptive and disparaging campaign against current SINOVAC board members that is meant to intimidate them and interfere with the stability and function of the current Board.

The Dissenting Investor Group’s hostile actions, baseless claims and wasteful litigation are evidence that it poses a direct threat to the value of your investment and the future of SINOVAC. Don’t let the Dissenting Investor Group, which is working in coordination with SAIF and is represented on SAIF’s Reconstituted Imposter Former Board, regain control of the Company. If the Reconstituted Imposter Former Board succeeds, it will put all valid shareholders’ future dividend payments at risk – this includes the current Board’s announced plans for an additional US$11.00 per common share cash dividend, contingent on the cancellation of the unauthorized PIPE shares, and its adopted policy to issue regular dividends out of surplus cash.

The current SINOVAC Board remains committed to its mission of restoring fairness, delivering value, and protecting the rights of all valid shareholders.

Your Vote is Important

Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment.

We urge you to keep SINOVAC’s Board in place and vote on the WHITE proxy card “AGAINST” Proposal 1 to remove the current Board and “AGAINST” Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders.

DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count!

If you have questions about how your vote can be counted, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S. and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@georgeson.com.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc.

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under “Category 1 Preventative Biological Products” and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government’s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

Important Additional Information and Where to Find It

In connection with SINOVAC’s Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission (“SEC”) and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC’s website, www.sec.gov, or from SINOVAC at its website: https://www.sinovac.com/en-us/Investors/sec_filings. You may also obtain copies of SINOVAC’s definitive proxy statement and other documents, free of charge, by contacting SINOVAC’s Investor Relations Department at ir@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company’s or Board’s control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company’s filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Contacts

Investor and Media Contact
FGS Global

Sinovac@fgsglobal.com

Cancer Vaccine (Preventative, Therapeutic) Market Research 2021-2031 | Innovations Drives the Industry Forward – Precision Immunotherapy and Personalized Medicine in Focus – ResearchAndMarkets.com




Cancer Vaccine (Preventative, Therapeutic) Market Research 2021-2031 | Innovations Drives the Industry Forward – Precision Immunotherapy and Personalized Medicine in Focus – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Vaccine Market (2025 Edition): Analysis By Type (Preventative, Therapeutic), By Technology Type, By Region, By Country: Market Insights and Forecast (2021-2031)” report has been added to ResearchAndMarkets.com’s offering.

The Global Cancer Vaccine market showcased growth at a CAGR of 6.68% during 2021-2024. The market was valued at USD 12.16 billion in 2024 which is expected to reach USD 20.88 billion in 2031. This report provides a complete analysis for the historical period of 2021-2024, the estimates of 2025 and the forecast period of 2026-2031.

The Cancer Vaccine Market is driven by innovations in immuno-oncology, increased prevalence of cancer, and growing investment in personalized medicine and biologics.

Preventative vaccines continue to dominate market share, particularly due to the success of HPV vaccination campaigns and government-supported immunization initiatives. Therapeutic vaccines are also witnessing increased adoption owing to advances in precision immunotherapy and their potential to treat a broad range of cancers by stimulating the patient’s immune response.

From a technology perspective, Recombinant Vaccines hold a major share in the market, fueled by their high efficacy, safety profile, and increasing R&D activities. Other emerging platforms such as viral vector-based and DNA-based vaccines are gaining traction, especially in clinical development pipelines.

Regionally, Americas leads the market, attributed to the presence of advanced healthcare infrastructure, high awareness, and strong regulatory support for vaccine development. However, Asia Pacific is expected to experience the fastest growth rate during the forecast period, driven by rising cancer incidence, increasing healthcare expenditure, and expanding biotechnology capabilities in countries such as China and India.

Scope of the Report

• The report analyses the Operation Theatre Management Market by Value (USD Million).
• The report analyses the Cancer Vaccine Market by Value (USD Million).
• The report presents the analysis of Cancer Vaccine Market for the historical period of 2021-2024, the estimated year 2025 and the forecast period of 2026-2031.
• The report analyses the Cancer Vaccine Market By Type (Preventative, Therapeutic)
• The report analyses the Cancer Vaccine Market By Technology Type (Recombinant Vaccine, Whole cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies).
• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Type, and By Technology Type.
• Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development.

Analyst Recommendations

• Leveraging AI and Bioinformatics for Precision Cancer Vaccine Development
• Pursue Fast-Track and Orphan Drug Designations

Competitive Positioning: Companies’ Product Positioning, Market Position Matrix, Market Share Analysis of Cancer Vaccine Market, Profile

• Merck & Co., Inc.
• Amgen Inc.
• Bristol Myers Squibb
• GSK plc
• Moderna, Inc.
• BioNTech SE
• Dendreon Pharmaceuticals LLC
• Gritstone bio, Inc.
• Nouscom S.r.l.
• Immunomic Therapeutics, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/q7vmih

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Sickle Cell Disease Treatment Market Research Report 2025-2035 | R&D Review, Patent Filling Trends, Regulatory Requirements, Pipeline Analysis – ResearchAndMarkets.com




Sickle Cell Disease Treatment Market Research Report 2025-2035 | R&D Review, Patent Filling Trends, Regulatory Requirements, Pipeline Analysis – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Sickle Cell Disease Treatment Market: Focus on Type, End User, and Country-Level Analysis – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

The global sickle cell disease treatment market is expected to experience substantial growth, driven by the increasing prevalence of sickle cell disease and the rising demand for more effective and accessible treatments. North America, particularly the U.S., leads the market in terms of market share and revenue. This dominance is attributed to factors such as better access to sickle cell disease treatments, strong government support, a robust research and innovation landscape, and specialized expertise. The U.S. benefits from an established healthcare infrastructure and significant government initiatives to improve access to sickle cell treatments, which further bolsters the global sickle cell disease treatment market in this region.

Additionally, the region is home to key pharmaceutical companies, which are heavily involved in the development and commercialization of therapies for sickle cell disease. These companies, along with research institutions, are driving advancements in treatments through strategic collaborations, shaping the future of the global sickle cell disease treatment market.

The global sickle cell disease treatment market in Asia-Pacific is projected to experience the fastest growth in the coming years. This growth is fuelled by increasing healthcare expenditure, a rising prevalence of sickle cell disease, and government initiatives aimed at expanding access to treatment. Countries in Asia-Pacific, such as China, India, and Japan, are witnessing a growing recognition of sickle cell disease, leading to increased healthcare investments and innovations in treatment. As the healthcare infrastructure in this region continues to improve and more government initiatives are introduced to address sickle cell disease, the global sickle cell disease treatment market will expand rapidly, creating significant growth opportunities.

While North America holds the largest market share in the global sickle cell disease treatment market, Europe also plays a key role. Growth in Europe is primarily driven by favourable reimbursement policies, a rising prevalence of sickle cell disease, and the focus of market players on expanding their offerings in the region. Countries like Germany, the U.K., and France are actively addressing the demand for sickle cell disease treatments, aided by regulatory frameworks that support new drug approvals and reimbursement. The global sickle cell disease treatment market in Europe continues to expand, supported by advancements in drug formulations and treatment options, and is expected to continue growing steadily in the coming years.

Regions such as South America, the Middle East, and Africa are also witnessing growth in the global sickle cell disease treatment market, although at a slower pace compared to Asia-Pacific. The growth in these regions is fuelled by rising awareness of sickle cell disease and increasing healthcare investments, especially in countries like Brazil, Mexico, and Nigeria. However, the lack of comprehensive healthcare infrastructure and access to advanced treatments in these regions remains a significant challenge for the global sickle cell disease treatment market.

The global sickle cell disease treatment market is highly competitive, featuring key players such as Pfizer Inc., bluebird bio, Inc., Generex Biotechnology Corporation, Emmaus Life Sciences, Inc., and Bristol Myers Squibb Company. These companies are heavily involved in the development and commercialization of new therapies for sickle cell disease. The global sickle cell disease treatment market is becoming increasingly competitive, with companies focusing on developing gene therapies, novel pharmacotherapies, and advanced drug delivery systems to meet the diverse needs of SCD patients.

In conclusion, the sickle cell disease treatment industry is poised for substantial growth over the next decade. While North America remains the dominant market in terms of market share and revenue, the Asia-Pacific region is set to experience the fastest growth, driven by increasing healthcare investments, rising awareness, and improvements in diagnostic capabilities. With advancements in treatment options, government initiatives, and an increasing focus on early diagnosis, the industry will continue to expand, offering significant opportunities for both established companies and new entrants in the field.

Key Topics Covered:

1. Markets: Industry Outlook

1.1 Trends: Current and Future Impact Assessment

1.2 R&D Review

1.3 Patent Filling Trend

1.3.1 By Country

1.3.2 By Company

1.4 Regulatory Requirements

1.5 Prevalence of Sickle Cell Disease in Different Regions and Countries

1.6 Pipeline Analysis

1.7 Market Dynamics Overview

1.7.1 Market Drivers

1.7.2 Market Restraints

1.7.3 Market Opportunities

2. Global Sickle Cell Disease Treatment Market (by End User)

2.1 Hospital

2.2 Specialty Clinics

2.3 Others

3. Global Sickle Cell Disease Treatment Market (by Type)

3.1 Bone Marrow Transplant

3.2 Blood Transfusion

3.3 Pharmacotherapy

3.4 Others (Gene Therapy)

4. Global Sickle Cell Disease Treatment Market (by Region)

4.1 North America

4.1.1 Key Market Participants in North America

4.1.2 Business Drivers

4.1.3 Business Challenges

4.1.4 Market Sizing and Forecast

4.1.4.1 North America Sickle Cell Disease Treatment Market, by End User

4.1.4.2 North America Sickle Cell Disease Treatment Market, by Country

4.1.4.2.1 U.S.

4.1.4.2.1.1 U.S. Sickle Cell Disease Treatment Market, by End User

4.1.4.2.2 Canada

4.1.4.2.2.1 Canada Sickle Cell Disease Treatment Market, by End User

4.2 Europe

4.3 Asia-Pacific

4.4 Rest of the World

5. Markets: Competitive Landscape and Company Profiles

5.1 Competitive Landscape

5.2 Company Profiles

5.2.1 Company Overview

5.2.2 Top Products / Product Portfolio

5.2.3 Top Competitors

5.2.4 Target Customers /End-Users

5.2.5 Key Personnel

5.2.6 Analyst View

• Novartis AG
• Pfizer, Inc.
• Bluebird bio, Inc,
• Generex Biotechnology
• Emmaus Life Sciences, Inc.
• Bristol-Myers Squibb Company
• Modus Therapeutics AB
• CRISPR Therapeutics
• GlycoMimetics, Inc.
• Editas Medicine, Inc.

6. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/qb2ihp

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Immunomodulator Therapeutics Global Market Research 2024-2030 | R&D Investments Fuel Next-Gen Immunomodulator Development Amid Patent Expiry – ResearchAndMarkets.com




Immunomodulator Therapeutics Global Market Research 2024-2030 | R&D Investments Fuel Next-Gen Immunomodulator Development Amid Patent Expiry – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Immunomodulator Therapeutics Market, Global, 2024-2030” report has been added to ResearchAndMarkets.com’s offering.

Revenue estimate for the base year 2024 is $93 billion with a CAGR of 9.0% for the study period 2024-2030.

This research service offers a comprehensive analysis of the global immunomodulator therapeutics market, specifically targeting inflammatory disorders in the immunology, gastrointestinal (GI), and dermatology segments. The report defines this market through products designed to modify and regulate pathological immune responses, either by inhibiting or suppressing them.

It categorizes the market by modality and key indications, providing a 6-year revenue forecast for global immunomodulator prescription drugs, alongside an analysis of key industry participants. The geographic scope encompasses North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and Latin America (LATAM), with regional revenue share estimates presented on a best-effort basis.

The report also discusses prevalent and emerging business models, analyzes trends in market access and reimbursement for immunomodulator therapies, and offers competitive assessments and revenue share analyses. It examines the factors driving and restraining growth in this space, offering insights into drug development trends, partnerships, and the investment landscape.

The report highlights key companies pioneering disruptive virtual care technologies and adjunctive therapies for effective disease management. Based on clinical needs, technological advancements, business models, and competitive dynamics, the report identifies the growth opportunities emerging from this space for market players and stakeholders to leverage. The base year is 2024, and the forecast period is from 2025 to 2030.

Growth Drivers

Rising Prevalence of Autoimmune and Inflammatory Diseases

Increasing prevalence of diseases like lupus, RA, Crohn’s disease, and psoriasis is driving demand for immunomodulators like tumor necrosis factor (TNF) inhibitors (e.g., Humira, Remicade) and JAK inhibitors (e.g., Xeljanz). The rapidly aging global population is more susceptible to chronic autoimmune conditions. It is further bolstering demand for treatments tailored to older adults, such as more tolerable biologics.

Biotech Advancements

Innovations in biotech platforms and advanced modalities such as CGT, bispecific antibodies, and RNA therapies are enhancing the efficacy and safety profiles of immunomodulators and driving the development of next-gen targeted therapies. Carisma Therapeutics Inc. and Moderna, Inc. have collaborated to use Carisma’s proprietary CAR-M technology and Moderna’s mRNA/lipid nanoparticles (LNP) platform to develop a macrophage engineering approach for autoimmune diseases.

Growing Investment in R&D

Increased funding from both public and private sectors is accelerating R&D efforts for discovering new therapies and improving existing ones. The NIH allocates significant funding for research on immunomodulatory therapies, fostering innovation. An increasing number of M&A deals demonstrate a growing focus on immunology by big pharma.

Success in Oncology and Expanding Applications

The success of immunotherapies in oncology has raised awareness and acceptance of similar approaches in treating autoimmune and inflammatory diseases. For example, Roche’s Gazyva/Gazyvaro (obinutuzumab), approved in 100 nations for several lymphoma types, is being investigated in the Phase III REGISTRY trial for lupus nephritis.

Growth Restraints

Immunomodulator Therapeutics: Growth Restraints, Global, 2025-2030

Stringent Regulatory Processes: Stringent regulatory processes for immunomodulatory treatment approval or the development of novel mechanisms of action, globally, can cause delays in market access and raise development expenses for pharmaceutical companies. Moreover, inadequate reimbursement/insurance coverage globally may deter wide-scale adoption, especially in public health systems or regions with limited healthcare resources. Inadequate coverage of high-cost new drugs would increase the expenses of managing long-term conditions, impacting patient compliance and market growth.

Potential Adverse Effects and Safety Concerns: Immunomodulators may have serious adverse effects, such as an elevated risk of infections and autoimmune responses. For example, checkpoint inhibitor use in autoimmune disease is linked to immune-related side effects that need to be carefully managed. Adverse outcomes and safety risks may lead to regulatory actions such as market recalls, limited prescriptions, and reduced patient confidence, challenging market uptake.

Patent Expiry: Expiry of blockbuster drug patents is leading to the introduction of biosimilars and generic versions, intensifying market competition, resulting in price erosions, and leading to a loss of sales revenue for branded products. For example, AbbVie’s blockbuster Humira, approved for several autoimmune conditions like RA, psoriasis, Crohn’s disease, and ankylosing spondylitis, started facing biosimilar competition in 2023.

Patient Inconvenience: Biotech advancements have facilitated the development of effective biologic therapies; however, therapy administration requires frequent injections or infusions, making it challenging for patients to adhere to their treatment regimens. It may affect overall patient satisfaction and treatment discontinuation.

The Impact of the Top 3 Strategic Imperatives on the Immunomodulator Therapeutics Industry

Disruptive Technologies

Why: There is an increasing incidence of autoimmune diseases, particularly impacting women. Limitations in existing therapies demand more targeted applications.

Analyst Perspective: A new wave of drug classes (JAK1, IL, calcineurin, TNF?, TYK2, PDE4), across small molecules, biologics, and cell and gene therapies, will emerge, offering enhanced efficacy and safety profiles for treating autoimmune and inflammatory conditions. There will be a growing trend towards combination therapies that utilize multiple mechanisms of action to achieve better clinical outcomes.

Internal Challenges

Why: The industry is moving toward an extended patent cliff, with several revenue-generating blockbuster drugs like Humira and Stelara losing their exclusivity, leading to revenue losses and increased biosimilar competition, creating an urgent need for pipeline growth, and driving increased research and development (R&D). Resource demands for R&D can strain budgets, especially for smaller biotech firms.

Analyst Perspective: Companies may increasingly seek strategic partnerships to share costs and risks, fostering innovation through collaborative R&D efforts. Companies that emphasize unique value propositions in these strategic alliances will be better positioned to access markets/fair pricing with drugs like JAK inhibitors and women-specific therapies. Payers will scrutinize clinical costs and patient outcomes to ensure balance and sustainable reimbursement models that reflect indication-specific needs and improve affordability.

Transformative Megatrends

Why: Healthcare systems are under pressure to contain current and future spending. Healthcare plan sponsors are considering their next moves as governments contemplate the impact of the Inflation Reduction Act (IRA) 2022, and associated price cuts in the United States.

Analyst Perspective: Firms will invest in adaptive trial designs for evidence generation to expedite approvals for novel MoA-based targeted therapies, advancing precision medicine going forward. Pharma companies will utilize diagnostic delivery services to improve patient access by partnering with telehealth/AI-enabled symptom monitoring platforms (e.g., Ada Health) and focus on an emerging market-expansion strategy. Focus on predictive convergence of drugs and digital therapeutics will likely personalize medicine and improve experiences and outcomes.

Scope of Analysis

• This research service provides a detailed overview of the global immunomodulator therapeutics market for immunology, gastrointestinal (GI), and dermatology inflammatory disorders.
• The report defines the market by products designed to treat diseases by modifying (inhibiting or suppressing) and regulating a pre-existing, pathological immune response. The market is further broken down by modality and key indications.
• It forecasts the potential revenue of global immunomodulator prescription drugs and provides a 6-year revenue forecast, including an analysis of industry participants.
• The research provides regional revenue share estimates of the overall market on a best-effort basis. The geographic scope includes North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA) and Latin America (LATAM).
• It discusses the most prevalent and emerging business models, market access, and reimbursement trends for immunomodulator therapies. It also covers revenue share analysis and competitive assessments and identifies key market trends.
• The report highlights the primary market drivers and restraints, drug development trends, partnerships, and investment and consolidation activities that affect market growth.
• It provides brief insights into game-changing companies developing disruptive virtual care technologies and adjunctive therapies for disease management.
• It identifies emerging growth opportunities for industry players based on clinical needs, technology trends, business models, and competitive outlooks.

Ecosystem in the Immunomodulator Therapeutics Sector

• Prevalence Trends
• Economic Burden
• Drug Development Trends – I&I
• Trial Landscape
• Clinical Trial Design Trends
• Regulatory Trends and Initiatives by Region
• Trends Advancing Market Growth
• Technology Solutions Across the Care Continuum
• Digital Solutions for R&D and Commercialization
• Business Models
• Mergers and Acquisitions M&As Assessment
• Venture Financing Assessment
• Competitive Environment
• Key Competitors

Growth Opportunity Universe in Immunomodulator Therapeutics Sector

• Antibody Therapies for I&I
• Women-centric Autoimmune Therapies
• Biosimilars for Emerging Markets
• Adjunctive Solutions for Disease Management and Adherence

Key Competitors

• Abbvie
• J&J
• Eli Lilly
• Astrazeneca
• Merck & Co
• Sanofi
• Novartis
• Amgen
• Pfizer
• Gsk
• Ucb
• Bristol Myers Squibb
• Roche
• Boehringer Ingelheim
• Argenx
• Regeneron Pharmaceuticals
• Novo Nordisk
• Bristol Myers Squibb
• Repertoire Immune Medicines
• Eli Lilly
• Pfizer
• Astrazeneca
• Roche
• Boehringer Ingelheim
• Merck & Co
• Sanofi
• Argenx
• Ucb
• Incyte
• Mallinckrodt Pharmaceuticals
• Asahi Kasei
• Afibbidy
• Swedish Orphan Biovitrum
• Anh Pharmaceuticals
• Vera Therapeutics
• Rigel Pharmaceuticals
• Astellas Pharma
• Takeda
• Chugai Pharma
• Mitsubishi Chemical
• Sun Pharmaceutical Industries
• Shanghai Pharmaceuticals Holding
• Zai Lab
• Innovent Biologics
• Kissei Pharmaceutical
• Biocon
• Otsuka Pharma
• Sumitomo Pharma
• Celltrion
• 3Bio
• Teva Pharma
• Kyowa Kirin
• Dr Reddy’s Lab
• Jiangsheng Henghui Pharmaceuticals
• Eva Pharma
• Roche
• Teva
• Astellas Pharma
• Hikma Pharmaceuticals Als
• Boehringer Ingelheim
• Sanofi
• Intas Pharmaceuticals Ltd
• Biocon
• Novartis
• Laboratorio Elea Phoenix S.A.
• Immunicore Holdings Plc
• Celltrion
• Sunshine Guojian Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/r/jxoywx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025




Number of Shares and Voting Rights of Innate Pharma as of July 3, 2025

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News:

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of July 3, 2025:

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations
NewCap
Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China




InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China

BEIJING–(BUSINESS WIRE)–#ADC–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794.

ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others.

Currently, there are no B7-H3 targeted therapies approved for marketing globally. B7-H3 is a type I transmembrane protein that is highly expressed in a variety of solid tumors. Due to its specific expression in tumor cells, it is considered a highly promising anti-tumor target.

Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, “ICP-B794 is developed from the Company’s proprietary ADC platform. The platform is designed to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology.”

With ongoing efforts to address the growing needs in solid tumors, InnoCare is committed to building a competitive drug portfolio aimed at treating a broad range of solid tumor indications. The Company is expanding the scope of its pipeline through a combination of targeted therapies, immune-oncology approaches, and cutting-edge ADC technology. The R&D team is focused on discovering and developing novel platforms that target various solid tumors, utilizing innovative technologies to identify and advance potential drug candidates that offer significant clinical benefits. InnoCare’s proprietary ADC technology platform, alongside promising precision medicine candidates like TRK inhibitor zurletrectinib (ICP-723), positions the Company to establish a strong presence in the field of solid tumor treatment.

About InnoCare

InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.

InnoCare Forward-looking Statements

This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.

Contacts

Media
Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investors
86-10-66609999

ir@innocarepharma.com